Acquisition strengthens global CRO capabilities

Resolian, a bioanalytical contract research organisation (CRO) specialising in drug metabolism and pharmacokinetics for small and large molecules, has successfully acquired Denali Medpharma, a leading bioanalytical CRO based in China. This strategic move positions Resolian with bioanalysis laboratory operations in the US, UK, Australia, and China, enabling the initiation of projects on four continents. The transfer of validated methods across labs allows therapeutic trials to extend to virtually any destination without the need to change bioanalytical CROs.

Resolian CEO Patrick Bennett expressed enthusiasm about the acquisition, stating: “The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market. Denali’s founders and core scientists are internationally recognised in pharmaceutical research and development analysis, and we are particularly excited to incorporate Denali’s expertise in oligo, mRNA, and liposomal analysis into Resolian’s portfolio of services. We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”

Denali CEO Min Meng, Ph.D., shared similar sentiments, stating: “The Denali team is thrilled to join Resolian. Founded by a group of US-trained bioanalytical experts in a state-of-the-art lab facility in China, Denali has consistently provided exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”

More information online